<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Eric M. Reiman</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>Banner Alzheimer's Institute<br>University of Arizona</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>180</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0001-5012-1883" target="_blank">0000-0001-5012-1883</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers)</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>[Biomarkers](/mechanisms/biomarkers-ad), Neuroimaging, Prevention</td>
</tr>
</table>
Eric M. Reiman
Overview
Eric M. Reiman is a leading researcher in the field of neurodegenerative diseases, affiliated with Banner Alzheimer's Institute and University of Arizona. Their research focuses on Biomarkers, Neuroimaging, Prevention, with particular emphasis on Alzheimer's Disease. With an h-index of 180, Reiman is among the most cited researchers in the neuroscience field[@orcid2026].
...<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Eric M. Reiman</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>Banner Alzheimer's Institute<br>University of Arizona</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>180</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0001-5012-1883" target="_blank">0000-0001-5012-1883</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers)</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>[Biomarkers](/mechanisms/biomarkers-ad), Neuroimaging, Prevention</td>
</tr>
</table>
Eric M. Reiman
Overview
Eric M. Reiman is a leading researcher in the field of neurodegenerative diseases, affiliated with Banner Alzheimer's Institute and University of Arizona. Their research focuses on Biomarkers, Neuroimaging, Prevention, with particular emphasis on Alzheimer's Disease. With an h-index of 180, Reiman is among the most cited researchers in the neuroscience field[@orcid2026].
Reiman's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease. Their research group has made significant contributions to the fields of Biomarkers, Neuroimaging, Prevention, publishing in high-impact journals including Nat Rev Neurol.
Based at Banner Alzheimer's Institute and University of Arizona, Reiman collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.
Research Focus
Disease Areas
- [Alzheimer's Disease](/diseases/alzheimers-disease)
Mechanisms of Interest
- [Biomarkers](/biomarkers)
- Neuroimaging
- Prevention
Programmatic Emphasis
Reiman's portfolio emphasizes mechanism-aware biomarker interpretation and translational hypothesis testing in Alzheimer's Disease[@long2019]. Their group typically links molecular process readouts to clinically meaningful outcomes, including cognitive trajectories, motor phenotypes, and disease staging endpoints when relevant[@jack2018].
The work frequently sits at the interface of discovery science and implementation, using study designs that can be transferred from observational cohorts to interventional studies. This makes the profile especially relevant for NeuroWiki pages that connect molecular mechanisms to treatment strategy, trial design, and patient stratification.
Methods and Data Strategy
Within the Biomarkers, Neuroimaging, Prevention domain, this research profile is most aligned with multimodal integration: combining imaging, biofluid, genomic, and clinical metadata to derive robust disease signatures. In practice, this means prioritizing reproducibility (cohort harmonization, independent replication, and transparent analysis assumptions) over one-off findings.
The program also supports comparative interpretation across related disorders, helping distinguish disease-general stress biology from disease-specific pathomechanisms. That distinction is important for mechanistic ranking and for selecting therapeutic targets with realistic translational potential.
Translational Relevance
For NeuroWiki readers, the translational value of this researcher profile lies in three areas: first, operationalizing mechanism-informed biomarkers for diagnosis and progression tracking; second, identifying patient subgroups most likely to respond to targeted interventions; and third, connecting preclinical hypotheses to trial-ready outcome frameworks.
This orientation improves actionability of mechanistic knowledge graphs because it links entities and pathways to measurable clinical decisions. Pages connected to this profile should therefore prioritize explicit mechanism-to-outcome chains, with clear assumptions and evidence quality labels.
Key Publications
[Brain imaging in Alzheimer's disease](https://doi.org/10.1038/nrneurol.2017.51). Nat Rev Neurol, 2017.[@brain2017]
Recent Research
Recent PubMed-indexed publications (2022-present):
[The Neighborhoods Study: Examining the social exposome in Alzheimer's disease and related dementias.](https://pubmed.ncbi.nlm.nih.gov/41230793/). Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025.
[Asymptomatic carotid artery stenosis is associated with increased Alzheimer's disease and non-Alzheimer's disease dementia risk.](https://pubmed.ncbi.nlm.nih.gov/39266210/). Stroke and vascular neurology. 2025.
[X-chromosome-wide association study for Alzheimer's disease.](https://pubmed.ncbi.nlm.nih.gov/39633006/). Molecular psychiatry. 2025.
[Serum detection of blood brain barrier injury in subjects with a history of stroke and transient ischemic attack.](https://pubmed.ncbi.nlm.nih.gov/38873494/). JVS-vascular science. 2024.
[Correlation of Presynaptic and Postsynaptic Proteins with Pathology in Alzheimer's Disease.](https://pubmed.ncbi.nlm.nih.gov/38542104/). International journal of molecular sciences. 2024.
Collaborators and Research Network
[Reisa A. Sperling](/researchers/reisa-sperling), [Jessica B. Langbaum](/researchers/jessica-langbaum), [Adam S. Fleisher](/researchers/adam-fleisher)
Institutional Context
Primary institutional links: [Banner Alzheimer's Institute](/banner-alzheimer's-institute), [University of Arizona](/institutions/university-of-arizona). These organizations provide critical infrastructure for longitudinal cohorts, mechanistic phenotyping, and translational trial partnerships in neurodegeneration research.
Open Questions and Future Directions
- How can Biomarkers, Neuroimaging, Prevention signals be standardized across cohorts and sites without losing disease-stage sensitivity?
- Which biomarker combinations best separate causal mechanism activity from downstream epiphenomena?
- What trial designs can most efficiently translate mechanistic findings in Alzheimer's Disease into clinically meaningful interventions?
External Links
- ORCID: [https://orcid.org/0000-0001-5012-1883](https://orcid.org/0000-0001-5012-1883)
- Google Scholar: [Search for Eric M. Reiman](https://scholar.google.com/scholar?q=author%3A%22Eric+M.+Reiman%22)
- PubMed: [Author search for Eric M. Reiman](https://pubmed.ncbi.nlm.nih.gov/?term=Eric+M.+Reiman%5BAuthor%5D)
See Also
- [Researchers and Institutions Index](/researchers)
- [Diseases Index](/diseases)
- [Mechanisms Index](/mechanisms)
References
[Unknown, Brain imaging in Alzheimer's disease (2017)](https://doi.org/10.1038/nrneurol.2017.51)
Unknown, ORCID profile for Eric M. Reiman (2026)
[Unknown, Long and Holtzman, Alzheimer disease an update on pathobiology and treatment strategies 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/30617256/)
[Jack et al, NIA AA research framework toward a biological definition of Alzheimer disease 2018 (2018)](https://pubmed.ncbi.nlm.nih.gov/29653606/)